These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 28198009)

  • 21. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify
    Lundy J; Harris M; Zalcberg J; Zimet A; Goldstein D; Gebski V; Borsaru A; Desmond C; Swan M; Jenkins BJ; Croagh D
    Front Oncol; 2021; 11():770022. PubMed ID: 34956889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
    Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
    Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Implications from a Prospective Cohort Study.
    Habib JR; Zhu Y; Yin L; Javed AA; Ding D; Tenior J; Wright M; Ali SZ; Burkhart RA; Burns W; Wolfgang CL; Shin E; Yu J; He J
    J Gastrointest Surg; 2021 Dec; 25(12):3149-3159. PubMed ID: 34244950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Droplet digital polymerase chain reaction detection of KRAS mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation.
    Mansour Y; Boubaddi M; Odion T; Marty M; Belleannée G; Berger A; Subtil C; Laurent C; Dabernat S; Amintas S
    Cancer Cytopathol; 2024 May; 132(5):274-284. PubMed ID: 38308613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial EUS-Guided FNA for the Surveillance of Pancreatic Cysts: A Study of Long-Term Performance of Tumor Markers.
    Rahal MA; DeWitt JM; Patel H; Schmidt CM; Ceppa EP; Simpson RE; Sherman S; Al-Haddad M
    Dig Dis Sci; 2022 Nov; 67(11):5248-5255. PubMed ID: 35229208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Preclinical Evaluation of Therapies in Cancer.
    Berry W; Croagh D
    Methods Mol Biol; 2018; 1725():31-40. PubMed ID: 29322406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endoscopic Ultrasound-Guided Fine-Needle Biopsies to Generate Preclinical Disease Models to Study Inflammation in Pancreatic Ductal Adenocarcinoma.
    Lundy J; Croagh D
    Methods Mol Biol; 2023; 2691():43-54. PubMed ID: 37355536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of pancreatic ductal adenocarcinoma.
    Sekita-Hatakeyama Y; Nishikawa T; Takeuchi M; Morita K; Takeda M; Hatakeyama K; Nakai T; Uchiyama T; Itami H; Fujii T; Mitoro A; Sho M; Ohbayashi C
    PLoS One; 2018; 13(3):e0193692. PubMed ID: 29494669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
    Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
    Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analyzing S100A6 expression in endoscopic ultrasonography-guided fine-needle aspiration specimens: a promising diagnostic method of pancreatic cancer.
    Zihao G; Jie Z; Yan L; Jing Z; Jing C; Xue L; Jing Z; Heng LW; Ru G; Jianyu H
    J Clin Gastroenterol; 2013 Jan; 47(1):69-75. PubMed ID: 22914344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
    Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
    World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
    Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
    Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
    Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
    Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.
    Reicher S; Boyar FZ; Albitar M; Sulcova V; Agersborg S; Nga V; Zhou Y; Li G; Venegas R; French SW; Chung DS; Stabile BE; Eysselein VE; Anguiano A
    Pancreas; 2011 Oct; 40(7):1057-62. PubMed ID: 21705950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.